New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life
source: pixabay.com

New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life

Dilated cardiomyopathy is a heart condition caused by a mutation in the RBM20 gene. This heart condition is unique because it can affect young adults. These individuals are at an…

Continue Reading New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life
Researchers Have Discovered a New Molecular Mechanism in Alzheimer’s Disease
Sourced from publicdomainpictures.net (https://www.publicdomainpictures.net/en/view-image.php?image=275669&picture=chemical-research)

Researchers Have Discovered a New Molecular Mechanism in Alzheimer’s Disease

At the Tufts University School of Medicine, researchers have uncovered a molecular mechanism that eventually leads to a build-up of amyloid beta, which is a major cause of Alzheimer's disease.…

Continue Reading Researchers Have Discovered a New Molecular Mechanism in Alzheimer’s Disease
EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment
stevepb / Pixabay

EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment

The European Medicines Agency has accepted Biogen's Marketing Authorization Application (MAA) for review. The application is for aducanumab, a treatment for Alzheimer's disease. As this condition faces an unmet medical…

Continue Reading EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment
New Research Will Target Tau’s Role in Alzheimer’s Disease
source: pixabay.com

New Research Will Target Tau’s Role in Alzheimer’s Disease

Researchers from Rensselaer Polytechnic Institute have been conducting research on tau proteins, specifically how it spreads from cell to cell. According to an article in Newswise, this team of researchers…

Continue Reading New Research Will Target Tau’s Role in Alzheimer’s Disease

Could TKIs Be Effective for Patients with Alzheimer’s, Parkinson’s, and Dementia?

What sort of treatments are available for patients with dementia and other neurodegenerative conditions? Are these treatments safe and effective? While these questions vary in answers, researchers are currently exploring…

Continue Reading Could TKIs Be Effective for Patients with Alzheimer’s, Parkinson’s, and Dementia?
New Vaccine Aims to Halt Alzheimer’s Disease Progression
kfuhlert / Pixabay

New Vaccine Aims to Halt Alzheimer’s Disease Progression

Medical professionals are constantly looking for treatments that will halt or even reverse the progression of Alzheimer's disease, and a new vaccine called E22W42 may be a large step in…

Continue Reading New Vaccine Aims to Halt Alzheimer’s Disease Progression

Until COVID-19 Disrupted our Lives, Alzheimer’s Disease Was Considered the Greatest Medical Challenge of the Century

Many different approaches have been offered by scientists to stem the overwhelming tide of Alzheimer’s disease (AD). Fifty percent of primary care physicians believe that the medical profession is not…

Continue Reading Until COVID-19 Disrupted our Lives, Alzheimer’s Disease Was Considered the Greatest Medical Challenge of the Century
First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial
source: pixabay.com

First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial

  Last week, clinical stage biopharmaceutical company Neurotrope announced that the first patient was dosed in a Phase 2 clinical trial to test the safety, efficacy, and tolerability of bryostatin-1…

Continue Reading First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial
Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases

According to a recent article in MedicalXpress, researchers in Japan led by Dr. Shinsuke Ishigaki and his team at Nagoya University, have identified new molecular details about tau’s activity. Alzheimer’s,…

Continue Reading Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases

Grant Goes to Elixiron Immunotherapeutics for Alzheimer’s Disease Treatment

According to an article from Newswire, the Alzheimer's Association is awarding Elixiron Immunotherapeutics one million dollars for work on their Alzheimer's treatment, EI1071. This money will go towards a clinical…

Continue Reading Grant Goes to Elixiron Immunotherapeutics for Alzheimer’s Disease Treatment

An Experimental Drug for Alzheimer’s is Being Tested to Treat Autism

Professor Illana Gozes and her team at Tel Aviv University recently developed NAP (CP201). It is an experimental drug that has been proven to be effective in the treatment of…

Continue Reading An Experimental Drug for Alzheimer’s is Being Tested to Treat Autism
New Blood Test Improves Alzheimer’s Disease Diagnosis
source: pixabay.com

New Blood Test Improves Alzheimer’s Disease Diagnosis

  A blood test that gives a more accurate diagnosis of Alzheimer’s disease was announced at the July 2020 International Conference of the Alzheimer’s Association. The Association estimates that approximately…

Continue Reading New Blood Test Improves Alzheimer’s Disease Diagnosis
Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
source: pixabay.com

Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets

  As of right now, there are no treatments for Alzheimer's disease, a progressive neurodegenerative disorder. However, that may soon change. A study led by UCLA researchers identified potential drug…

Continue Reading Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
source: pixabay.com

Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease

  According to a recent article in BioSpace, Biogen and Eisai have launched a new preclinical Phase III trial of BAN2401 to treat pre-clinical Alzheimer's disease. The new study follows…

Continue Reading Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
source: pixabay.com

Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward

As reported in Parkinson's News Today, an investigational therapy to treat patients with Alzheimer's disease and Parkinson’s disease has had its Phase 2 trial approved by the central institutional review…

Continue Reading Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
source: pixabay.com

Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease

  Parkinson’s News Today recently published an article containing new information about biomarkers in Alzheimer’s disease that can be linked to the early stages of Parkinson’s disease. Many people with…

Continue Reading Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
Image by Markus Spiske from Pixabay

Scientists Can Identify Schwann Cells Using Novel Bar Code Technique

Scientists and researchers have long known how important glial cells are to the nervous system. Not only do these cells make up a majority of cells within the central nervous…

Continue Reading Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases
source: pixabay.com

Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases

Anavex Life Sciences Corporation has recently announced that they will conduct a clinical trial for their small molecule, ANAVEX®3-71. This therapy is intended to treat neurodegenerative and neurodevelopmental conditions, such…

Continue Reading Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases

Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier

It is acknowledged in the medical community that clumps of misfolded tau proteins and amyloid-β are markers of Alzheimer’s disease. The evidence presented in recent article in Nature, shows that…

Continue Reading Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier
Caring for Someone with Alzheimer’s Disease During COVID-19
5239640 / Pixabay

Caring for Someone with Alzheimer’s Disease During COVID-19

COVID-19 is difficult for many of us. We are facing an unprecedented time and questions abound. How do we handle our work, our families, our health? If you are a…

Continue Reading Caring for Someone with Alzheimer’s Disease During COVID-19
Klotho Gene Variant Reduces Alzheimer’s Disease Risk in High-Risk Adults
source: pixabay.com

Klotho Gene Variant Reduces Alzheimer’s Disease Risk in High-Risk Adults

  According to MedPage Today, carriers of the gene variation APOE4 are much more at risk of developing Alzheimer's disease. However, researchers found that one copy of the Klotho gene mutation,…

Continue Reading Klotho Gene Variant Reduces Alzheimer’s Disease Risk in High-Risk Adults
Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification
source: pixabay.com

Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification

  In February 2020, Epigenetics published results of a study reporting that researchers have found an early sign of Alzheimer’s disease in DNA modification (methylation) that had been overlooked. Patients…

Continue Reading Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification
Close Menu